IMPRESS study shows continuing tyrosine kinase inhibitors after progression not effective
the ONA take:
According to new data presented at the European Society for Medical Oncology 2014 Congress in Madrid, Spain, patients with non-small cell lung cancer (NSCLC) that have developed resistance to gefitinib do not experience any statistically significant improvement in progression-free survival from continued treatment with gefitinib in combination with chemotherapy.
For the IMPRESS study, researchers identified 265 patients from 71 centers in Europe and the Asia Pacific region. Patients received chemotherapy plus either gefitinib or placebo. They found that the gefitinib group did not have a statistically significant improvement in progression-free survival versus the placebo group. It is too early to determine whether there was difference in overall survival, which the researchers say needs to be closely monitored in the future.
The researchers say that this study helps to determine the standard of treatment after a patient with NSCLC acquires resistance to epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) after an initial response. The results suggest that clinicians should not prescribe EGFR TKIs pub chemotherapy when patients with NSCLC have progressed after treatment with an EGFR TKI. The results were surprising to the researchers, as they believed an improvement in progression-free survival would be observed.
Patients resistant to gefitinib do not experience any significant improvement with gefitinib.
Patients whose lung cancer has developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival from continued treatment with the drug in addition to chemotherapy, a phase III trial presented at the ESMO 2014 Congress has shown.
The IMPRESS trial is a randomised phase III study that compared continuation of gefitinib in addition to chemotherapy against chemotherapy alone in patients with lung cancer that carried mutations in the EGFR cell surface receptor.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|